SCM
TCRT icon

Stevens Capital Management’s Alaunos Therapeutics TCRT Stock Holding History

Stevens Capital Management’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-185
Closed -$152K – 1140
2016
Q2 		$152K Buy
+185
New +$201K 0.01% 808
2016
Q1 		– Sell
-249
Closed -$310K – 1104
2015
Q4 		$310K Buy
+249
New +$412K 0.01% 684
2014
Q4 		– Sell
-254
Closed -$101K – 1220
2014
Q3 		$101K Buy
254
+1
+0.4% +$482 ﹤0.01% 935
2014
Q2 		$153K Buy
253
+159
+169% +$88.5K ﹤0.01% 964
2014
Q1 		$65K Buy
+94
New +$63K ﹤0.01% 1030

Other funds holding TCRT

TS
Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MVP
Miller Value Partners Sarasota, Florida $383M AUM 38.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BGA
Belmont Global Advisors Dallas, Texas $106M AUM 2.89% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Stevens Capital Management's TCRT Position: Q3 2016 in Review

Stevens Capital Management sold out of Alaunos Therapeutics (TCRT) in Q3 2016, closing a stake of 185 shares — an estimated $152K sold.

Stevens Capital Management first reported a position in TCRT in Q1 2014 and held it in 5 quarters. The position peaked at $310K in Q4 2015. 140 funds tracked by Wall St. Rank hold TCRT as of Q3 2016.

  • Stevens Capital Management reported no remaining Alaunos Therapeutics position as of Q3 2016 after selling out during the quarter.
  • Stevens Capital Management sold 185 Alaunos Therapeutics shares in Q3 2016, an estimated $152K.
  • Stevens Capital Management first reported a position in Alaunos Therapeutics in Q1 2014 and held it in 5 quarters.
  • Stevens Capital Management's Alaunos Therapeutics position peaked at $310K in Q4 2015.
  • 140 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q3 2016.

Based on Stevens Capital Management's 13F filing for Q3 2016, filed 8 Nov 2016.